Browsing by Author "Wang, Danxin"

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing
    (Wiley, 2015-07) Birdwell, Kelly A.; Decker, Brian; Barbarino, Julia M.; Peterson, Josh F.; Stein, C. Michael; Sadee, Wolfgang; Wang, Danxin; Vinks, Alexander A.; He, Yijing; Swen, Jesse J.; Leeder, J. Steven; van Schaik, RHN; Thummel, Kenneth E.; Klein, Teri E.; Caudle, Kelly E.; MacPhee, Iain A.M.; Department of Medicine, IU School of Medicine
    Tacrolimus is the mainstay immunosuppressant drug used after solid organ and hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and intermediate metabolizers) generally have decreased dose-adjusted trough concentrations of tacrolimus as compared with those who are CYP3A5 nonexpressers (poor metabolizers), possibly delaying achievement of target blood concentrations. We summarize evidence from the published literature supporting this association and provide dosing recommendations for tacrolimus based on CYP3A5 genotype when known (updates at www.pharmgkb.org).
  • Thumbnail Image
    Item
    PharmVar GeneFocus: CYP3A5
    (ASCPT, 2022-12) Rodriguez-Antona, Cristina; Savieo, Jessica L.; Lauschke, Volker M.; Sangkuhl, Katrin; Drögemöller, Britt I.; Wang, Danxin; van Schaik, Ron H. N.; Gilep, Andrei A.; Peter, Arul P.; Boone, Erin C.; Ramey, Bronwyn E.; Klein, Teri E.; Whirl-Carrillo, Michelle; Pratt, Victoria M.; Gaedigk, Andrea; Medicine, School of Medicine
    The Pharmacogene Variation Consortium (PharmVar) catalogs star (*) allele nomenclature for the polymorphic human CYP3A5 gene. Genetic variation within the CYP3A5 gene locus impacts the metabolism of several clinically important drugs, including the immunosuppressants tacrolimus, sirolimus, cyclosporine, and the benzodiazepine midazolam. Variable CYP3A5 activity is of clinical importance regarding tacrolimus metabolism. This GeneFocus provides a CYP3A5 gene summary with a focus on aspects regarding standardized nomenclature. In addition, this review also summarizes recent changes and updates including the retirement of several allelic variants and provides an overview of how PharmVar CYP3A5 star allele nomenclature is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC).
  • Thumbnail Image
    Item
    PharmVar GeneFocus: CYP3A5
    (Wiley, 2022) Rodriguez-Antona, Cristina; Savieo, Jessica L.; Lauschke, Volker M.; Sangkuhl, Katrin; Drögemöller, Britt I.; Wang, Danxin; van Schaik, Ron H. N.; Gilep, Andrei A.; Prakasam Peter, Arul; Boone, Erin C.; Ramey, Bronwyn E.; Klein, Teri E.; Whirl-Carrillo, Michelle; Pratt, Victoria M.; Gaedigk, Andrea; Medicine, School of Medicine
    The Pharmacogene Variation Consortium (PharmVar) catalogs star (*) allele nomenclature for the polymorphic human CYP3A5 gene. Genetic variation within the CYP3A5 gene locus impacts the metabolism of several clinically important drugs, including the immunosuppressants tacrolimus, sirolimus, cyclosporine, and the benzodiazepine midazolam. Variable CYP3A5 activity is of clinical importance regarding tacrolimus metabolism. This GeneFocus provides a CYP3A5 gene summary with a focus on aspects regarding standardized nomenclature. In addition, this review also summarizes recent changes and updates, including the retirement of several allelic variants and provides an overview of how PharmVar CYP3A5 star allele nomenclature is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC).